Sanofi and Regeneron Report Phase 3 Results for Dupixent in Children Aged 6-11 with Atopic Dermatitis

Sanofi and Regeneron today announced Phase 3 trial results for Dupixent (dupilumab) in children aged 6 to 11 years with moderate-to-severe atopic dermatitis. The trial met its primary endpoint, demonstrating a significantly higher rate of clear or almost clear skin compared to placebo at week 16. These results led to FDA approval of Dupixent for children aged 6 and older.